Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-02
2009-12-01
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S302000, C514S367000, C514S375000, C546S114000, C546S115000, C548S153000, C548S217000, C548S302700
Reexamination Certificate
active
07625923
ABSTRACT:
The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia,wherein R1, R2, R5, X, Y and n are defined herein.
REFERENCES:
patent: 3239345 (1966-03-01), Hodge et al.
patent: 3948933 (1976-04-01), Fontanella
patent: 4036979 (1977-07-01), Asato
patent: 4411890 (1983-10-01), Momany et al.
patent: 4959361 (1990-09-01), Walser et al.
patent: 5179080 (1993-01-01), Rothkopf
patent: 5403817 (1995-04-01), Sekinger et al.
patent: 5482921 (1996-01-01), Seckinger et al.
patent: 5488064 (1996-01-01), Sher et al.
patent: 5491134 (1996-02-01), Sher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5556909 (1996-09-01), Desai
patent: 5605877 (1997-02-01), Schafer et al.
patent: 5612359 (1997-03-01), Murugesan et al.
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5811374 (1998-09-01), Bertram et al.
patent: 6011029 (2000-01-01), Ding et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6310095 (2001-10-01), Sebti et al.
patent: 6365615 (2002-04-01), Kelly et al.
patent: 6531612 (2003-03-01), Gabriel et al.
patent: 6566367 (2003-05-01), Bakthavatchalam et al.
patent: 6670386 (2003-12-01), Sun et al.
patent: 6710064 (2004-03-01), Launay et al.
patent: 6897225 (2005-05-01), Sircar et al.
patent: 6974823 (2005-12-01), Hamilton
patent: 6992102 (2006-01-01), Hamann et al.
patent: 2002/0133004 (2002-09-01), Sekiyama et al.
patent: 2004/0019063 (2004-01-01), Sun et al.
patent: 2004/0181064 (2004-09-01), Sun et al.
patent: 2005/0059652 (2005-03-01), Hamann et al.
patent: A-82875/87 (1998-06-01), None
patent: 2126187 (1971-05-01), None
patent: 3809390 (1989-09-01), None
patent: 0272594 (1988-06-01), None
patent: 0493323 (1992-07-01), None
patent: 1004583 (2000-05-01), None
patent: 1125925 (2002-02-01), None
patent: 1503244 (1978-03-01), None
patent: 52083686 (1977-07-01), None
patent: WO8907110 (1989-08-01), None
patent: WO8907111 (1989-08-01), None
patent: WO9304081 (1993-03-01), None
patent: WO9405668 (1994-03-01), None
patent: WO9414817 (1994-07-01), None
patent: WO 96/19458 (1996-06-01), None
patent: WO9719086 (1997-05-01), None
patent: WO9721993 (1997-06-01), None
patent: WO9730992 (1997-08-01), None
patent: WO 97/49709 (1997-12-01), None
patent: WO9822461 (1998-05-01), None
patent: WO9825929 (1998-06-01), None
patent: WO9838192 (1998-09-01), None
patent: WO9854966 (1998-12-01), None
patent: WO9900353 (1999-01-01), None
patent: WO9901124 (1999-01-01), None
patent: WO9902224 (1999-01-01), None
patent: WO9902514 (1999-01-01), None
patent: WO9903848 (1999-01-01), None
patent: WO9907692 (1999-02-01), None
patent: WO9924416 (1999-05-01), None
patent: WO9927890 (1999-06-01), None
patent: WO9928324 (1999-06-01), None
patent: WO9943653 (1999-09-01), None
patent: WO9954318 (1999-10-01), None
patent: WO9954319 (1999-10-01), None
patent: WO9954330 (1999-10-01), None
patent: WO9965913 (1999-12-01), None
patent: WO9967252 (1999-12-01), None
patent: WO9967253 (1999-12-01), None
patent: WO0000485 (2000-01-01), None
patent: WO0001389 (2000-01-01), None
patent: WO0013508 (2000-03-01), None
patent: WO0059874 (2000-10-01), None
patent: WO0072845 (2000-12-01), None
patent: WO0107052 (2001-02-01), None
patent: WO0116108 (2001-03-01), None
patent: WO0116133 (2001-03-01), None
patent: WO0116139 (2001-03-01), None
patent: WO0130781 (2001-05-01), None
patent: WO0146195 (2001-06-01), None
patent: WO0154498 (2001-08-01), None
patent: WO0170684 (2001-09-01), None
patent: WO0172705 (2001-10-01), None
patent: WO0200653 (2002-01-01), None
patent: WO0218335 (2002-03-01), None
patent: WO03011824 (2003-02-01), None
patent: WO03066636 (2003-08-01), None
Wollweber et al., European Journal of Medicinal Chemisty 1980, 15(2) ( CAS Abstract Only).
Banker et al., “Modern Pharmaceutices, 3rd. ed.”, Marcel Dekker, New York 1996, pp. 451 and 596.
Beyler et al., J. Am. Med. W. Assoc., 23(8):708-721.
Boris et al., Steroids, 15:61-71.
Bundgaard, “Design of Prodrugs”, Elsevier Science Publishers 1985, tabe of contents.
Bundgaard, “Design and Application of Prodrugs”, Harwood Academic Publishers 1991, pp. 113-191.
Chalepakis et al., Cell, 53:371-382.
Delaisi et al., J. Steroid Biochem. Molec. Biol. 41(3-8)773-7.
Dyatkin Tet Lett 38(12):2065-6.
Edwards et al., Bioorg. Med. Chem. Lett 9:1003-8.
Fernand Labrie, Int'l Braz. J. Urol. 30(1):3-11.
Gori et al., Boll.-Soc. Ital. Boil. Sper. 42:1596-1599.
Gori et al., Boll.-Soc. Ital. Boil. Sper. 42:1600-1601.
Heiser, in Methods in Mol. Biol. 130:117-134.
Hempstock et al., J. Med. Food 2(3-4):243-246.
Hershberger et al., P.S.E.B.M. 83:175-180.
Hiroaka et al., Cancer Res., 47:6560-6564.
Imakura et al., Chem. Pharm. Bull. 40(7):1691-1696.
Iseki, K. et al., Tet. 53(10) 3513-26.
Issartel et al., 1996, CAS 125:316198.
Johannsson et al., J. Clin. Endocr. Met. 82(3):727-734.
Kakigami et al., Chem. Pharm. Bull. 46(1):42-52.
Lalezari et al., J Het Chem 20(2) 483-485 (1983).
Matsuki et al., Chem. Pharm. Bull. 42(1):9-18.
Milata et al., Org. Prep. Proc. Int'l, 25(6):703-704.
Minesita et al., Cancer Research 25:1168-1175.
Navone et al., Clin. Canc. Res. 3:2493-2500.
Okuda et al., J. Urology 145:188-191.
Palovich et al., 2000, CAS 134:25357.
Panouse et al., Ann. Pharm. Franc., 2000:291-302.
Rodbard in Ligand Assay, Masson Publishing USA Inc., 1981, pp. 45-101.
Schuur et al., J. Biol. Chem. 271(12):7043-7051.
Suzuki et al., J. Steroid Chem. Mol. Biol. 37(4):559-567.
Talon et al., Br. J. Pharmacol., 134(7):1523-31.
Taplin et al. J. Cell Biochem. 91(3):483-490.
Uozumi, Tet Lett 42:407-410.
Uozumi et al., Tet Lett 42:411-414.
Venable, Am. J. Anat. 119:263-270.
Wermuth et al. in The Practice of Medicinal Chemistry, Academic Press, 1996, pp. 671-696.
Wolft “Burger's Medicinal Chemistry, 5th ed., Part 1”, John Wiley & Sons 1995, pp. 975-977.
Montes de Oca et al., Arkivoc, 390-403 (2003).
U.S. Appl. No. 10/984,502, filed Nov. 9, 2004, Bi et al.
U.S. Appl. No. 11/048,437, filed Feb. 1, 2005, Nirschl et al.
U.S. Appl. No. 11/048,439, filed Feb. 1, 2005, Hamann et al.
U.S. Appl. No. 11/070,020, filed Mar. 2, 2005, Li et al.
U.S. Appl. No. 11/070,025, filed Mar. 2, 2005, Li et al.
Banz, W.J. et al., “Effects of Soy Protein and Soy Phytoestrogens on Symptoms Associated with Cardiovascular Disease in Rats”, Journal of Medicinal Food, vol. 2, Nos. 3-4, pp. 271-273 (1999).
Boeijen, A. et al., “Combinatorial Chemistry of Hydantoins”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2375-2380 (1998).
Bourguet, W. et al., “Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α”, Nature, vol. 375, pp. 377-382 (1995).
Brzozowski, A.M. et al., “Molecular basis of agonism and antagonism in the oestrogen receptor”, Nature, vol. 389, pp. 753-758 (1997).
Evans, R.M., “The Steroid and Thyroid Hormone Receptor Superfamily”, Science, vol. 240, pp. 889-895 (1988).
Grese, T.A. et al., “Molecular determinants of tissue selectivity in estrogen receptor modulators”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 14105-14110 (1997).
Hamann, L.G. et al., “Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)”, J. Med. Chem., vol. 42, No. 2, pp. 210-212 (1999).
Hamann, L.G. et al., “Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Re
Hamann Lawrence
Nirschl Alexandra
Sun Chongqing
Sutton James C.
Wang Tammy
Bristol--Myers Squibb Company
Gibbons Maureen S.
Rodney Burton
Saeed Kamal A
LandOfFree
Bicyclic modulators of androgen receptor function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic modulators of androgen receptor function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic modulators of androgen receptor function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4141396